Announcement PDF ASX ANNOUNCEMENT Invion Limited ABN 76 094 730 417 Suite 2, Level 11, 385 Bourke Street Melbourne, VIC 3000 P: +61 3 9692 7222 W: www.inviongroup.com INVESTMENT CONFERENCE PRESENTATION MELBOURNE (AUSTRALIA) 19 February 2026: Invion Limited (ASX: IVX) (“Invion” or the “Company”) will be presenting at the EMERGENCE 2026 Investment Conference in Sydney today. Attached is the presentation that Invion’s Executive Chair and CEO, Prof Thian Chew, will be using for his presentation. This announcement was approved for release by the Board of Directors. ____________________________________________ Sign up at Invion’s Investor Hub to receive regular updates, provide feedback and participate in discussions: https://investors.inviongroup.com/ Investor and Media enquiries: Thian Chew (Chairman & CEO) T: +61 3 9692 7222 E: investor@inviongroup.com Brendon Lau (Investor & Media Relations) M: +61 409 341 613 E: brendon.lau@inviongroup.com About Invion Invion is a life-science company that is leading the global research and development of the Photosoft™ technology for the treatment of a range of cancers, atherosclerosis and infectious diseases. Invion holds the global exclusive license to the Photosoft technology for multiple cancer and non-cancer disease indications. Invion is listed on the ASX (ASX: IVX). Find out more at www.Inviongroup.com. About Next Generation Photodynamic Therapy (NGPDT) Invion is developing PhotosoftTM technology as a novel Next Generation Photodynamic Therapy (NGPDT). NGPDT uses non-toxic photosensitisers and light to selectively kill cancer cells and promote an anti-cancer immune response. Less invasive than surgery and with minimal side effects, NGPDT offers an alternative treatment option aimed at achieving complete tumour regression and long-lasting remission. NGPDT has also demonstrated broad-spectrum activity across multiple infectious diseases, including bacteria, fungi and viruses. Photosoft has the potential to address the global challenge of antibiotic-resistant “superbugs”. CORPORATE PRESENTATION February 2026 ASX: IVX Next Generation Photodynamic Therapy (PDT) for Cancers and Infectious Diseases 2 DISCLAIMER The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Invion Limited (Company). In preparing this presentation, the Company did not take into account the investment objectives, financial situation and particular needs of any particular investor. Further advice should be obtained from a professional investment adviser before taking any action on any information dealt with in the presentation. Those acting upon any information without advice do so entirely at their own risk. Whilst this presentation is based on information from sources which are considered reliable, no representation or warranty, express or implied, is made or given by or on behalf of the Company, any of its directors, or any other person about the accuracy, completeness or fairness of the information or opinions contained in this presentation. No responsibility or liability is accepted by any of them for that information or those opinions or for any errors, omissions, misstatements (negligent or otherwise) or for any communication written or otherwise, contained or referred to in this presentation. Accordingly, neither the Company nor any of its directors, officers, employees, advisers, associated persons or subsidiaries are liable for any direct, indirect or consequential loss or damage suffered by any person as a result of relying upon any statement in this presentation or any document supplied with this presentation, or by any future communications in connection with those documents and all of those losses and damages are expressly disclaimed. Any opinions expressed reflect the Company’s position at the date of this presentation and are subject to change. CLINICAL INFLEXION POINT ACROSS MULTIPLE CANCERS 3 COMPANY HIGHLIGHTS Clinical Results: Multiple Cancers • Successful Ph II Prostate Cancer Results (investigator led trial) • Promising early results from ongoing Ph I/II Non-Melanoma Skin Cancer trial • Upcoming anogenital cancer trial at Peter Mac • US FDA Orphan Drug Designation for anal cancer Key Advantages • Platform technology that is scalable across multiple indications • Selectively targets multiple cancers and activates the immune system* • Strong clinical safety profile, and demonstrated efficacy signals • Theragnostic potential (violet light fluoresces red light kills the cancers) Key Partnerships • Peter MacCallum Cancer Centre: Research partnerships (anogenital cancer trial) • Hanlim Pharm: Funding oesophageal cancer program leading to clinical trial (IV) including support by Korean Drug Development Fund), GBM preclinical studies also funded • Protect Animal Health Inc. Funding animal cancer development program (including companion animal trials) Photosoft is only activated by specific wavelengths of light to selectively regress or fluoresce cancers *Based on preclinical studies at Peter Mac & Hudson Institute Photosoft is a ground-breaking technology that overcomes many significant shortcomings & side effects of approved PDT treatments 4 Photodynamic Therapy (PDT) consists of three elements: Minimally invasive modality for treating cancer that specifically identifies and destroys cancer cells whilst leaving healthy cells unharmed THE PHOTOSOFTTM ADVANTAGE NEXT GENERATION IMPROVEMENT ON APPROVED PDTs 1 2 3 Combines photosensitiser compound with light- induced activation Generates reactive oxygen species (“ROS”) causing damage to only targeted cells Direct cell death along with activation of immune response Generation of reactive O2 03 Light Necrosis Apoptosis Autophagy Photosensitiser accumulation in tumour tissue 01 Cellular localisation 02 Cellular damage 04 Cell death via 05 5 LEAD CANCER DRUG CANDIDATE INV043 MULTIPLE CANCERS, ATTRACTIVE THERAPEUTIC PROFILE PhotosoftTM Photosoft is a portfolio of hundreds of photosensitisers protected by over ten patent families. Lead Cancer Drug Candidate: INV043 Non-toxic, safe and limited side effects at up to 100x therapeutic dose Selectively absorbed by cancer cells (Warburg effect) Combination with Immune Checkpoint Inhibitors2 improves response rate from 12% to 80% Potency: ~600x greater photoxicity than Talaporfin (widely used photosensitiser) Effective in regressing multiple types of cancer in human trials and in vivo1 1 In preclinical studies including with the Hudson Institute of Medical Research and Peter MacCallum Cancer Centre 2 Immune Checkpoint Inhibitor (ICI) therapies are part of the Immunotherapy market of cancer treatments Stimulate the body’s natural immune response 6 PHASE II PROSTATE CANCER CLINICAL TRIAL RESULTS INVESTIGATOR-LED PROSTATE CANCER STUDY USING INV043* * Licensor funded study as previously disclosed to the market SAFE AND WELL TOLERATED EFFICACY: 40-44% RESPONSE RATE ▪ No serious adverse events and all adverse events were mild ▪ Current treatment options (e.g., radiotherapy, chemotherapy and surgery) carry significant risks of side effects ▪ PSMA-PET Results: 7 patients were negative 3 months post treatment (~44% response) ▪ RECIST Framework: 40% positive response 3 months post treatment (1 complete regression) and another 40% had stable disease ▪ 41 patients dosed (16 post-COVID with readouts, 25 during COVID lockdown limited readouts) ▪ Each patient – 6 cycles of PDT treatment over 9 weeks TREATMENT PROTOCOL 0 1 2 3 4 5 6 7 Recorded Adverse Events During After (16 patients x 6 questionnaires = 96 recordings) SAFETY REVIEW COMMITTEE FINDINGS – INITIAL PATIENT GROUP 7 PHASE I/II NON-MELANOMA SKIN CANCER TRIAL ▪ No adverse events identified & no pain reported (vs. current PDT treatments) ▪ Observable reduction in the NMSC lesion size after one treatment cycle ▪ Highlights INV043’s potential as a diagnostic with suspected cancers fluorescing under violet light Change in size of NMSC lesions treated and untreated lesions* SEM = Standard Error of the Mean *Data integrity check (data lock) by the clinical trial manager has not been completed for the full data set. Further analysis will be conducted at the next stage of the trial. Untreated Lesions Treated Lesions Findings from Safety Review Committee (SRC) (initial patient group of 6) DIAGNOSTIC POTENTIAL 8 INV043 FLUORESCES CANCERS UNDER VIOLET LIGHT Photos from three different patients in the NMSC trial INV043 appears to localise in the lesion site, which is consistent with preclinical data that showed accumulation in the tumour cells. Natural light, no INV043 Violet light, no INV043 Violet light, INV043 Patient 101-002 from Ph I/II NMSC Trial: Day 1 of the treatment Potential for INV043 to assist surgeons to more accurately remove cancers • Primary pancreatic (Human PANC1) cancer • Cancers received INV043 at 0.1 mg/kg by IT (primary tumours) or IP (metastatic tumours) injection • After 1 hour, INV043 visualised as fluorescence localised to tumour mass and margins when illuminated using violet light Animal studies at Hudson Institute • INV043 was seen concentrated within metastatic nodules 16 hours after IP injection • Small metastatic nodules on the liver visible to naked eye when illuminated using violet light Combi therapy: ~65% improvement in effectiveness vs. ICI alone IMPROVING IMMUNOTHERAPY OUTCOMES, PARTNERSHIP POTENTIAL 9 COMBINATION WITH IMMUNE CHECKPOINT INHIBITORS (ICI) 1 https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2762389 2 https://announcements.asx.com.au/asxpdf/20220530/pdf/459ffkjbvdpjrg.pdf 3 https://investors.inviongroup.com/announcements/6228975 HUDSON INSTITUTE:. ~65% IMPROVEMENT IN TUMOUR VOLUME (TNBC, INTRATUMORAL)2 PETER MAC: ~80% RESPONSE RATE vs. 12.5% ICI ONLY (ANAL SCC CANCER, TOPICAL)3 *** INV043+PD1 vs Vehicle = p=0.001 ** INV043+PD1 vs PD1 p=0.0037 * INV043 vs Vehicle p=0.0397 *** ** * 7/10, no measurable tumour. 8th mouse histology, no evidence of tumour cells 1 The Phase I/II NMSC trial uses an adaptive study design means recruitment numbers and timelines may change to accelerate the evaluation of INV043 2 Hanlim Pharm with support from the South Korean Government’s KDDF are funding the Oesophageal Cancer studies 3 Pet pharmaceutical company, Protect Animal Health (TPEX: 7850), are funding an animal cancer development program (including companion animal trials) using a different compound within Invion’s portfolio CANCER (HUMAN) Prostate Cancer (Funded by RMWC) Non-Melanoma Skin Cancers (Topical)1 Anogenital Cancers (Topical) Oesophageal (Funded by Hanlim/KDDF)2 CANCER (ANIMALS) Companion Animal Cancer Studies (Funded by Protect)3 MULTIPLE CLINICAL TRIALS AND INDICATIONS CANCER: TARGET INDICATIONS AND TIMEFRAMES DISEASE AREA 1H2024 2H2024 1H2025 2H2025 >CY26 PreClinical Phase 1 Phase 2 10 Follow up and monitoring Adaptive study design Completed LUCRATIVE COMPANION ANIMAL MARKET OPPORTUNITY COLLABORATION WITH PROTECT ANIMAL HEALTH 1) https://www.avma.org/resources/pet-owners/petcare/cancer-pets 2) https://www.zionmarketresearch.com/news/pet-cancer-therapeutics-market New Market Potential • Reinforces Photosoft as a platform technology with multiple market opportunities • Invion has hundreds of proprietary Photosoft compounds in its portfolio Funded Studies • Protect to fund and undertake evaluation studies (in vitro, in vivo and companion animal trials) • Invion retains all existing and new IP rights Growing Opportunity • Fast growing market with ~50% of dogs over the age of 10 diagnosed with cancer • Global pet cancer market forecast to grow 9.7% CAGR (2025-2034) to US$12.1B Founded in 2019, listed on Taipei Exchange (TPEX:7850) Focused on advanced therapeutics for companion animals 250 pet pharmacies and 900+ veterinary clinics Collaborates with global pharma partners and academic institutions NEED FOR MORE AFFORDABLE NEW TREATMENTS CREATING IMPACT FOR TREATING CANCERS GLOBALLY 12 Cost of new FDA drugs in 2023 jumped 35% YoY at median price of US$300K1, affordability impacts accessibility for most of the world’s patients. Trends towards personalised medicines and targeted therapies2 Half of new drugs are orphan3, which cost 5.5 times more than non-orphan3 Works across multiple cancers without need to personalise – precision with less complexity INV043 is a small molecule based therapy that is highly scalable Photosoft solution has lower development and manufacturing costs Equipment and treatment process is not complex - helps reach a larger patient base Commercial Rationale for Photosoft 1 https://www.reuters.com/business/healthcare-pharmaceuticals/prices-new-us-drugs-rose-35-2023-more-than-previous-year-2024-02-23/ 2 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10290406/#:~:text=There%20has%20been%20significant%20policy,being%20approved%20in%20recent%20years 3 https://www.mdpi.com/1999-4923/15/6/1761#:~:text=Additionally%2C%20the%20cost%20of%20ADC,a%20barrier%20for%20some%20patients DR SOUMYA RAI PROGRAM DIRECTOR • Dental surgeon, clinical and business mgmt experience • Resident, JLN House and Research Centre, SAIL • Asst Prof. Rungta College Dental Sciences and Research • MBA HKUST 13 PROF SEBASTIAN MARCUCCIO MEDICINAL CHEMISTRY • Pharma/drug discovery and dev (co-inventor IVX PDT patents) • Founder / Director Advanced Molecular Technologies • Previously in Pharmaceutical Chemicals Research, CSIRO • Adj. Prof. La Trobe University, PhD Organic Chemistry ANU ALEXANDER BENNETT TECHNICAL ADVISOR, LIGHT DEVICES • 35+ years in R&D, manufacturing and commercialisation of scientific instrumentation incl. ISO certifications • GM Forensic Light Sources, Rofin Australia. • Led Medical Light Source trial for PDT in skin cancers Peter MacCallum Cancer Centre DR DANIEL GARAMA SCIENTIFIC ADVISOR • Heads proteomics & mitochondrial disease team at the Hudson Institute of Medical Research • Expert in cancer biology, proteomics & translational research • Affiliate at Monash & Melbourne universities • Published in Science, Nature; recipient of global research awards DR AMY PRAWIRA MEDICAL CONSULTANT • Founder/CEO, Obatica Pty Ltd (engaged to assist with clinical trials) • 12+ years in clinical oncology and trials • Investigator with experience in over 90 early phase clinical trials • Head, Cancer Trials and Research Unit, Prince of Wales Hospital (Sydney) PROF THIAN CHEW EXECUTIVE CHAIRMAN & CEO • Co-Founder, Chronic Airway Therapeutics • Advisory Board, Stanford Medicine CARE • Executive Director, Goldman Sachs • Director, KPMG Consulting, Senior Manager KPMG • A/Prof HKUST, V/Prof UCL Global Bus School Health, MBA/MA Wharton THE RIGHT EXPERTISE FOR SUCCESS EXPERIENCED TEAM PROF ROBERT RAMSAY SCIENTIFIC ADVISOR • 30+ years research in cancer biology &translational medicine • Senior Scientist, Ex-Co Head Gastrointestinal Program, Peter MacCallum Cancer Centre • Ex-President Australian Society for Medical Research (ASMR) • Hon.Professor, Dept Oncology & Clinical Pathology, Uni. Melb LOUISE WHITE MANUFACTURING AND QUALITY • 35+ years in the pharmaceutical industry, 13 years in vaccine manufacturing, CSL, Partner SeerPharma • Experience in virology R&D, bacterial vaccines production, quality control and production planning • Registered auditor for APVMA For more information, go to www.inviongroup.com Investor and Media enquiries: Thian Chew (Chairman & CEO) Brendon Lau (Investor & Media Relations) T: +61 3 9692 7222 M: +61 409 341 613 E: investor@inviongroup.com E: brendon.lau@inviongroup.com